Table 3.
Results of the Baseline Case Evaluation of Liquid Biopsy Testing in Anti-HER2 Therapy in Advance Breast Cancer
Baseline Case Metastatic Her2-Positive Breast Cancer | ||||
---|---|---|---|---|
Strategy | Cost | Incremental Cost | Effectiveness (QALY) | Incremental Effectiveness (QALY) |
Liquid biopsy | US $185,318.52 (555,955,586.746 COP) |
US $7,333.17 (21,999,534.710 COP) |
0.533466647 | 0.00042256 |
No liquid biopsy | US $177,985.35 (533,956,052.037 COP) | 0.533889206 |
Abbreviation: COP, Colombian Pesos.